Clinical Trial Update: Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer [Phase 1]

View source ↗

Summary

Pfizer conducted a Phase 1 trial of erlotinib with or without the investigational agent PF-02341066 in patients with non-small cell lung cancer; the study is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PF-02341066 (PF-02341066)
• Tarceva (erlotinib) (erlotinib)

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2013-01-14